Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect

Anticancer Research

Volumn 24, Issue 5 A, 2004, Pages 2705-2712

  Kawano, Takeshi ^a   Horiguchi Yamada, Junko ^a   Iwase, Satsuki ^a   Akiyama, Masaharu ^a   Furukawa, Yusuke ^b   Kano, Yasuhiko ^c   Yamada, Hisashi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c TOCHIGI CANCER CENTER   (Japan)

Author keywords

Apoptosis; c Myc; Chronic myeloid leukemia; Cyclin D1; Depsipeptide; Histone deacetylase inhibitor; Imatinib mesylate; MEK

Indexed keywords

BCR ABL PROTEIN; CASPASE 3; CYCLIN D1; DEPSIPEPTIDE; FR 901228; HISTONE DEACETYLASE INHIBITOR; HISTONE H4; IMATINIB; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; TRICHOSTATIN A;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVATION; FLUORESCENCE MICROSCOPE; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACETYLATION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CYCLIN D1; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; HISTONES; HUMANS; HYDROXAMIC ACIDS; IMMUNOBLOTTING; K562 CELLS; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MYC; PYRIMIDINES;

EID: 6444226076     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Sattler M and Griffin JD: Mechanisms of transformation by the BCR/ABL oncogene. Int J Hematol 73: 278-291, 2001.
2. Kurzrock R, Kantarjian HM, Druker BJ and Talpaz M: Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 138: 819-830, 2003.
3. Kantarjian HM, Talpaz M, O'Brien S, Kurzrock R, Gutterman J, Keating MJ, McCredie KB and Freireich EJ: Chronic myelogenous leukemia-progress at the M. D. Anderson Cancer Center over the past two decades and future directions: First Emil J. Freireich Award Lecture. Clin Cancer Res 3: 2723-2733, 1997.
4. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM and Fanning S: Effects of a selective inhibitor of the AbI tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566, 1996.
5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S and Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Eng J Med 344: 1031-1037, 2001.
6. von Bubnoff N, Peschel C and Duyster J: Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 17: 829-838, 2003.
7. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R and Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038-1042, 2001.
8. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202, 2001.
9. Kouraklis G and Theocharis S: Histone deacetylase inhibitors and anticancer therapy. Curr Med Chem Anti-Canc Agents 2: 477-484, 2002.
10. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N and Horinouchi S: Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 48 Suppl 1: S20-26, 2001.
11. Narlikar GJ, Fan HY and Kingston RE: Cooperation between complexes that regulate chromatin structure and transcription. Cell 108: 475-487, 2002.
12. Yoshida M, Kijima M, Akita M and Beppu T: Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174-17179, 1990.
13. Yoshida M, Hoshikawa Y, Koseki K, Mori K and Beppu T: Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. J Antibiot (Tokyo) 43: 1101-1106, 1990.
14. Ueda H, Nakajima H, Hori Y, Goto T and Okuhara M: Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem 58: 1579-1583, 1994.
15. Fecteau KA, Mei J and Wang HC: Differential modulation of signaling pathways and apoptosis of ras-transformed 10T1/2 cells by the depsipeptide FR901228. J Pharmacol Exp Ther 300: 890-899, 2002.
16. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y and Furukawa Y: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97: 1999-2007, 2001.
17. Kitamura K, Hoshi S, Koike M, Kiyoi H, Saito H and Naoe T: Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. Br J Haematol 108: 696-702, 2000.
18. Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, Marks PA, Richon VM and La Quaglia MP: The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 61: 3591-3594, 2001.
19. Nimmanapalli R, Fuino L, Stobaugh C, Richon V and Bhalla K: Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101: 3236-3239, 2003.
20. Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P and Grant S: Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res 63: 2118-2126, 2003.
21. Kawano T, Horiguchi-Yamada J, Iwase S, Furukawa Y, Kano Y and Yamada H: Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it. Mol Cell Biochem 258: 25-33, 2004.
22. Kawano T, Horiguchi-Yamada J, Saito S, Iwase S, Furukawa Y, Kano Y and Yamada H: Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells. Leukemia Res 28: 623-629, 2004.
23. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, Waterhouse NJ, Trapani JA and Johnstone RW: Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63: 4460-4471, 2003.
24. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA and Schrump DS: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94: 504-513, 2002.
25. Sandor V, Senderowicz A, Merlins S, Sackett D, Sausville E, Blagosklonny MV and Bates SE: P21-dependent G1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 83: 817-825, 2000.